{"id":8562,"date":"2026-01-30T17:34:00","date_gmt":"2026-01-30T13:34:00","guid":{"rendered":"https:\/\/omanet.om\/en\/news\/economy\/drugmakers-rush-boost-us-presence\/"},"modified":"2026-01-31T01:12:30","modified_gmt":"2026-01-30T21:12:30","slug":"drugmakers-rush-boost-us-presence","status":"publish","type":"post","link":"https:\/\/omanet.om\/en\/news\/economy\/drugmakers-rush-boost-us-presence\/","title":{"rendered":"Drugmakers Accelerate US Expansion: What the Tariff Threat Means for Your Investment Strategy"},"content":{"rendered":"<style>\r\n@keyframes hitv3sog-fadein{from{opacity:0;transform:translateY(14px)}to{opacity:1;transform:translateY(0)}}\r\n@keyframes hitv3sog-slideup{from{opacity:0;transform:translateY(20px)}to{opacity:1;transform:translateY(0)}}\r\n@keyframes hitv3sog-pulse{0%,100%{box-shadow:0 0 14px #dc262688}50%{box-shadow:0 0 32px #dc2626,0 0 60px #dc262655}}\r\n@keyframes hitv3sog-shimmer{0%,100%{opacity:0.3;transform:scaleX(0.4)}50%{opacity:1;transform:scaleX(1)}}\r\n@keyframes hitv3sog-glow{0%,100%{opacity:0.6}50%{opacity:1}}\r\n@keyframes hitv3sog-badge{from{opacity:0;transform:scale(0.8)}to{opacity:1;transform:scale(1)}}\r\n<\/style><style>\r\n.hitv3sogw{container-type:inline-size;width:100%;max-width:970px;margin:0 auto;box-sizing:border-box}\r\n.hitv3soga{display:flex;flex-direction:row;align-items:center;justify-content:space-between;width:100%;box-sizing:border-box;text-decoration:none;color:#fff;font-family:-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,system-ui,sans-serif;position:relative;overflow:hidden;cursor:pointer;background:linear-gradient(135deg,#111118 0%,#080808 100%);border:1.5px solid rgba(255,255,255,0.08);border-radius:14px;gap:20px;padding:20px 40px;transition:border-color .2s}\r\n.hitv3soga:hover{border-color:#dc262688}\r\n.hitv3sogg1{position:absolute;inset:0;background:radial-gradient(ellipse at 50% 0%,rgba(220,38,38,0.35),transparent 65%);pointer-events:none;z-index:0}\r\n.hitv3sogg2{position:absolute;bottom:0;left:0;right:0;height:45%;background:radial-gradient(ellipse at 50% 100%,rgba(220,38,38,0.15),transparent 70%);pointer-events:none;z-index:0}\r\n.hitv3soggl{position:absolute;top:0;left:8%;right:8%;height:1px;background:linear-gradient(90deg,transparent,#dc262666,transparent);z-index:0}\r\n.hitv3sogc{position:relative;z-index:1;display:flex;flex-direction:column;justify-content:center;flex:1;min-width:0}\r\n.hitv3sogh{font-size:24px;font-weight:800;line-height:1.15;letter-spacing:-.03em;color:#fff;text-shadow:0 2px 12px rgba(0,0,0,.4);margin:2px 0;white-space:nowrap;overflow:hidden;text-overflow:ellipsis}\r\n.hitv3sogs{font-size:13px;color:rgba(255,255,255,.6);line-height:1.4;margin-top:3px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis}\r\n.hitv3sogbl{display:none;flex-direction:column;gap:5px;margin-top:9px;align-self:flex-start}\r\n.hitv3sogbi{display:flex;align-items:center;font-size:11px;color:rgba(255,255,255,.55);font-weight:500}\r\n.hitv3sogct{position:relative;z-index:1;flex-shrink:0;display:flex;flex-direction:column;align-items:center}\r\n.hitv3sogbtn{display:inline-flex;align-items:center;gap:6px;padding:10px 24px;background:#dc2626;background-image:linear-gradient(180deg,rgba(255,255,255,.12) 0%,transparent 100%);color:#fff;font-size:14px;font-weight:700;border-radius:8px;white-space:nowrap;box-shadow:0 0 20px #dc262666;border:none;cursor:pointer;font-family:inherit;transition:filter .15s,transform .15s}\r\n.hitv3sogbtn:hover{filter:brightness(1.15);transform:scale(1.04)}\r\n.hitv3sogbr{font-size:9px;color:rgba(255,255,255,.18);text-align:center;margin-top:5px;letter-spacing:.1em;text-transform:uppercase}\r\n\/* \u2500\u2500 Compact horizontal: 380\u2013599px (like 320\u00d7100) \u2500\u2500 *\/\r\n@container (min-width:380px) and (max-width:599px){\r\n  .hitv3soga{padding:12px 22px;gap:12px;min-height:100px}\r\n  .hitv3sogh{font-size:16px}\r\n  .hitv3sogs{display:none}\r\n  .hitv3sogbtn{padding:7px 16px;font-size:11px}\r\n}\r\n\/* \u2500\u2500 Mobile\/card: < 380px (like 300\u00d7250) \u2500\u2500 *\/\r\n@container (max-width:379px){\r\n  .hitv3soga{flex-direction:column;align-items:center;justify-content:space-between;min-height:260px;padding:22px 22px;gap:10px}\r\n  .hitv3sogc{align-items:center;text-align:center}\r\n  .hitv3sogh{font-size:22px;white-space:normal}\r\n  .hitv3sogs{font-size:11px;white-space:normal}\r\n  .hitv3sogbl{display:flex;align-self:center;text-align:left}\r\n  .hitv3sogbtn{width:100%;justify-content:center;padding:12px 20px}\r\n}\r\n\/* \u2500\u2500 Wide: >= 600px (leaderboard style) \u2500\u2500 *\/\r\n@container (min-width:600px){\r\n  .hitv3soga{min-height:90px}\r\n}\r\n<\/style><!-- HiT Land Banner \u2014 Container Query Responsive -->\r\n<div class=\"hitv3sogw\">\r\n<a class=\"hitv3soga\" href=\"https:\/\/hit.land\/services\/web-app-development\" target=\"_blank\" rel=\"noopener nofollow\" style=\"animation:hitv3sog-fadein 0.7s ease both;animation-delay:0s;\">\r\n  <div class=\"hitv3sogg1\" style=\"animation:hitv3sog-glow 3s ease-in-out infinite;\"><\/div>\r\n  <div class=\"hitv3sogg2\"><\/div>\r\n  <div class=\"hitv3soggl\" style=\"animation:hitv3sog-shimmer 3s ease-in-out infinite;\"><\/div>\r\n  \r\n  <div class=\"hitv3sogc\">\r\n    \r\n    <div style=\"display:inline-flex;align-self:flex-start;align-items:center;gap:6px;background:rgba(255,255,255,0.08);border:1px solid rgba(255,255,255,0.18);backdrop-filter:blur(8px);-webkit-backdrop-filter:blur(8px);border-radius:20px;padding:3px 10px 3px 7px;margin-bottom:clamp(5px,0.6vw,9px);animation:hitv3sog-badge 0.5s ease both;\"><span style=\"display:inline-block;width:6px;height:6px;border-radius:50%;background:#dc2626;flex-shrink:0;\"><\/span><span style=\"font-size:clamp(8px,0.9vw,10px);font-weight:700;letter-spacing:0.07em;color:rgba(255,255,255,0.88);text-transform:uppercase;white-space:nowrap;\">EXCLUSIVE OMAN OFFER<\/span><\/div>\r\n    <div class=\"hitv3sogh\" style=\"animation:hitv3sog-slideup 0.7s ease both;animation-delay:0.15s;\">Websites For <span style=\"color:#dc2626;\">Omani Businesses.<\/span><\/div>\r\n    <div class=\"hitv3sogs\" style=\"animation:hitv3sog-slideup 0.7s ease both;animation-delay:0.3s;\">Empower your brand with custom digital solutions designed for high conversion and market dominance.<\/div>\r\n    <div class=\"hitv3sogbl\"><div class=\"hitv3sogbi\"><span style=\"display:inline-block;width:5px;height:5px;border-radius:50%;background:#dc2626;flex-shrink:0;margin-right:7px;\"><\/span><span>Responsive designs built for growth<\/span><\/div><div class=\"hitv3sogbi\"><span style=\"display:inline-block;width:5px;height:5px;border-radius:50%;background:#dc2626;flex-shrink:0;margin-right:7px;\"><\/span><span>Fast loading with smart automation<\/span><\/div><\/div>\r\n  <\/div>\r\n  \r\n  <div class=\"hitv3sogct\">\r\n    <button class=\"hitv3sogbtn\" style=\"animation:hitv3sog-pulse 2.5s ease-in-out infinite;animation-delay:1s;\">Build Your Free Website <span style=\"opacity:.9;\">\u2192<\/span><\/button>\r\n    <div class=\"hitv3sogbr\">hit.land<\/div>\r\n  <\/div>\r\n<\/a>\r\n<\/div>\n<p><\/p>\n<p>Global pharmaceutical companies are significantly increasing their manufacturing capacities and stockpiling inventory in the United States amid the Trump administration\u2019s consideration of imposing a 100% tariff on imported branded and patented medicines.<\/p>\n<p>While tariff enforcement is deferred for companies investing in domestic manufacturing, this policy has already accelerated project timelines, prompted price reductions, and encouraged direct-to-consumer sales strategies.<\/p>\n<p>Several leading drugmakers have secured multi-year tariff exemptions through pricing agreements and commitments to the administration\u2019s TrumpRx.gov platform. Companies such as Eli Lilly, Johnson &amp; Johnson, and Merck have pledged billions of dollars to expand their US operations, aiming to avoid penalties.<\/p>\n<p>Here is a summary of the key actions by major pharmaceutical firms to mitigate supply chain risks and provide investor reassurance:<\/p>\n<p><strong>Pfizer<\/strong> reached a deal with President Donald Trump on September 30 to invest $70 billion in US research, development, and manufacturing. In return, Pfizer received a three-year exemption from pharmaceutical tariffs.<\/p>\n<p><strong>GlaxoSmithKline (GSK)<\/strong> plans to invest $30 billion over five years in US-based research and development and supply chain infrastructure.<\/p>\n<p><strong>Eli Lilly<\/strong> is committing at least $27 billion to establish four manufacturing plants across Alabama, Virginia, and Texas, to strengthen medical supply chains.<\/p>\n<p><strong>Johnson &amp; Johnson<\/strong> will increase its US investments by 25%, totaling $55 billion over the next four years. This includes constructing four plants, with confirmed locations in Wilson, North Carolina, and at Fujifilm Biotechnologies&#8217; facility in Holly Springs, North Carolina.<\/p>\n<p><strong>Roche<\/strong> announced a $50 billion US investment over five years, with an additional $550 million allocated to expand its diagnostic manufacturing hub in Indianapolis. The company is also more than doubling its investment to about $2 billion at its drug manufacturing site in Holly Springs, North Carolina.<\/p>\n<p><strong>AstraZeneca<\/strong> commits $50 billion by 2030 to US manufacturing, including a major new drug substance facility in Virginia\u2014its largest single-site global investment\u2014alongside expansions in Maryland, Massachusetts, California, Indiana, and Texas.<\/p>\n<p><strong>Novartis<\/strong> plans $23 billion over five years to build and expand ten US facilities, including six new manufacturing plants and an expanded R&amp;D site in San Diego expected to create over 1,000 jobs.<\/p>\n<p><strong>Sanofi<\/strong> aims to invest at least $20 billion through 2030 to boost US manufacturing and research, increasing capacity via direct investments and partnerships with domestic manufacturers.<\/p>\n<p><strong>Biogen<\/strong> will invest an additional $2 billion to expand its North Carolina manufacturing plants, focusing on gene-targeting therapies and automation. The company operates seven facilities in the state, with an eighth scheduled to open in late 2025.<\/p>\n<p><strong>Merck<\/strong> has begun constructing a $3 billion pharmaceutical plant in Virginia as part of a $70 billion-plus investment to expand domestic manufacturing and research. It will also invest $1 billion in a Delaware plant to produce biologics and cancer drug Keytruda, potentially creating over 4,500 jobs. Additionally, Merck opened a $1 billion facility in North Carolina in March and plans $895 million in investments at its Kansas manufacturing and R&amp;D site through 2028.<\/p>\n<p><strong>Amgen<\/strong> plans to invest $900 million to expand its Ohio manufacturing facility, raising total investments in the state to $1.4 billion and adding 750 jobs. It also committed $1 billion to build a second facility in Holly Springs, North Carolina, and over $600 million to develop a new R&amp;D center in Thousand Oaks, California. Furthermore, Amgen is investing $650 million to expand manufacturing in Juncos, Puerto Rico, expected to create nearly 750 jobs.<\/p>\n<p><strong>Novo Nordisk<\/strong> emphasized its strong US manufacturing presence in August, describing itself as &#8220;very US-centric and US-focused,&#8221; positioning itself well for tariff challenges.<\/p>\n<p><strong>AbbVie<\/strong> committed $100 billion over the next decade to US-based research and development as part of a three-year agreement with the Trump administration aimed at lowering drug prices. With 11 US manufacturing sites, AbbVie considers itself largely insulated from tariff impacts due to strategic inventory management.<\/p>\n<p><strong>Gilead Sciences<\/strong> announced $11 billion in new US investments earlier this year, bringing its total pledged investment to $32 billion. The company has begun work on a pharmaceutical development and manufacturing hub in Foster City, California, and is developing two additional sites.<\/p>\n<p><strong>Cipla<\/strong>, an Indian pharmaceutical company, is expanding its US manufacturing capacity for complex respiratory products at its advanced facilities in Fall River, Massachusetts, and Central Islip, New York.<\/p>\n<p><strong>CSL<\/strong>, an Australian firm, plans to invest $1.5 billion over the next five years to manufacture plasma-derived therapies, increasing its US footprint.<\/p>\n<p>These substantial commitments signal a robust reshaping of the pharmaceutical manufacturing landscape in the United States driven by evolving trade policies and a strategic focus on domestic production.<\/p>\n<p><style>\r\n@keyframes hitl8gak-fadein{from{opacity:0;transform:translateY(14px)}to{opacity:1;transform:translateY(0)}}\r\n@keyframes hitl8gak-slideup{from{opacity:0;transform:translateY(20px)}to{opacity:1;transform:translateY(0)}}\r\n@keyframes hitl8gak-pulse{0%,100%{box-shadow:0 0 14px #dc262688}50%{box-shadow:0 0 32px #dc2626,0 0 60px #dc262655}}\r\n@keyframes hitl8gak-shimmer{0%,100%{opacity:0.3;transform:scaleX(0.4)}50%{opacity:1;transform:scaleX(1)}}\r\n@keyframes hitl8gak-glow{0%,100%{opacity:0.6}50%{opacity:1}}\r\n@keyframes hitl8gak-badge{from{opacity:0;transform:scale(0.8)}to{opacity:1;transform:scale(1)}}\r\n<\/style><style>\r\n.hitl8gakw{container-type:inline-size;width:100%;max-width:970px;margin:0 auto;box-sizing:border-box}\r\n.hitl8gaka{display:flex;flex-direction:row;align-items:center;justify-content:space-between;width:100%;box-sizing:border-box;text-decoration:none;color:#fff;font-family:-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,system-ui,sans-serif;position:relative;overflow:hidden;cursor:pointer;background:linear-gradient(135deg,#111118 0%,#080808 100%);border:1.5px solid rgba(255,255,255,0.08);border-radius:14px;gap:20px;padding:20px 40px;transition:border-color .2s}\r\n.hitl8gaka:hover{border-color:#dc262688}\r\n.hitl8gakg1{position:absolute;inset:0;background:radial-gradient(ellipse at 50% 0%,rgba(220,38,38,0.35),transparent 65%);pointer-events:none;z-index:0}\r\n.hitl8gakg2{position:absolute;bottom:0;left:0;right:0;height:45%;background:radial-gradient(ellipse at 50% 100%,rgba(220,38,38,0.15),transparent 70%);pointer-events:none;z-index:0}\r\n.hitl8gakgl{position:absolute;top:0;left:8%;right:8%;height:1px;background:linear-gradient(90deg,transparent,#dc262666,transparent);z-index:0}\r\n.hitl8gakc{position:relative;z-index:1;display:flex;flex-direction:column;justify-content:center;flex:1;min-width:0}\r\n.hitl8gakh{font-size:24px;font-weight:800;line-height:1.15;letter-spacing:-.03em;color:#fff;text-shadow:0 2px 12px rgba(0,0,0,.4);margin:2px 0;white-space:nowrap;overflow:hidden;text-overflow:ellipsis}\r\n.hitl8gaks{font-size:13px;color:rgba(255,255,255,.6);line-height:1.4;margin-top:3px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis}\r\n.hitl8gakbl{display:none;flex-direction:column;gap:5px;margin-top:9px;align-self:flex-start}\r\n.hitl8gakbi{display:flex;align-items:center;font-size:11px;color:rgba(255,255,255,.55);font-weight:500}\r\n.hitl8gakct{position:relative;z-index:1;flex-shrink:0;display:flex;flex-direction:column;align-items:center}\r\n.hitl8gakbtn{display:inline-flex;align-items:center;gap:6px;padding:10px 24px;background:#dc2626;background-image:linear-gradient(180deg,rgba(255,255,255,.12) 0%,transparent 100%);color:#fff;font-size:14px;font-weight:700;border-radius:8px;white-space:nowrap;box-shadow:0 0 20px #dc262666;border:none;cursor:pointer;font-family:inherit;transition:filter .15s,transform .15s}\r\n.hitl8gakbtn:hover{filter:brightness(1.15);transform:scale(1.04)}\r\n.hitl8gakbr{font-size:9px;color:rgba(255,255,255,.18);text-align:center;margin-top:5px;letter-spacing:.1em;text-transform:uppercase}\r\n\/* \u2500\u2500 Compact horizontal: 380\u2013599px (like 320\u00d7100) \u2500\u2500 *\/\r\n@container (min-width:380px) and (max-width:599px){\r\n  .hitl8gaka{padding:12px 22px;gap:12px;min-height:100px}\r\n  .hitl8gakh{font-size:16px}\r\n  .hitl8gaks{display:none}\r\n  .hitl8gakbtn{padding:7px 16px;font-size:11px}\r\n}\r\n\/* \u2500\u2500 Mobile\/card: < 380px (like 300\u00d7250) \u2500\u2500 *\/\r\n@container (max-width:379px){\r\n  .hitl8gaka{flex-direction:column;align-items:center;justify-content:space-between;min-height:260px;padding:22px 22px;gap:10px}\r\n  .hitl8gakc{align-items:center;text-align:center}\r\n  .hitl8gakh{font-size:22px;white-space:normal}\r\n  .hitl8gaks{font-size:11px;white-space:normal}\r\n  .hitl8gakbl{display:flex;align-self:center;text-align:left}\r\n  .hitl8gakbtn{width:100%;justify-content:center;padding:12px 20px}\r\n}\r\n\/* \u2500\u2500 Wide: >= 600px (leaderboard style) \u2500\u2500 *\/\r\n@container (min-width:600px){\r\n  .hitl8gaka{min-height:90px}\r\n}\r\n<\/style><!-- HiT Land Banner \u2014 Container Query Responsive -->\r\n<div class=\"hitl8gakw\">\r\n<a class=\"hitl8gaka\" href=\"https:\/\/hit.land\/services\/web-app-development\" target=\"_blank\" rel=\"noopener nofollow\" style=\"animation:hitl8gak-fadein 0.7s ease both;animation-delay:0s;\">\r\n  <div class=\"hitl8gakg1\" style=\"animation:hitl8gak-glow 3s ease-in-out infinite;\"><\/div>\r\n  <div class=\"hitl8gakg2\"><\/div>\r\n  <div class=\"hitl8gakgl\" style=\"animation:hitl8gak-shimmer 3s ease-in-out infinite;\"><\/div>\r\n  \r\n  <div class=\"hitl8gakc\">\r\n    \r\n    <div style=\"display:inline-flex;align-self:flex-start;align-items:center;gap:6px;background:rgba(255,255,255,0.08);border:1px solid rgba(255,255,255,0.18);backdrop-filter:blur(8px);-webkit-backdrop-filter:blur(8px);border-radius:20px;padding:3px 10px 3px 7px;margin-bottom:clamp(5px,0.6vw,9px);animation:hitl8gak-badge 0.5s ease both;\"><span style=\"display:inline-block;width:6px;height:6px;border-radius:50%;background:#dc2626;flex-shrink:0;\"><\/span><span style=\"font-size:clamp(8px,0.9vw,10px);font-weight:700;letter-spacing:0.07em;color:rgba(255,255,255,0.88);text-transform:uppercase;white-space:nowrap;\">EXCLUSIVE OFFER<\/span><\/div>\r\n    <div class=\"hitl8gakh\" style=\"animation:hitl8gak-slideup 0.7s ease both;animation-delay:0.15s;\">Your Website <span style=\"color:#dc2626;\">Should Sell.<\/span><\/div>\r\n    <div class=\"hitl8gaks\" style=\"animation:hitl8gak-slideup 0.7s ease both;animation-delay:0.3s;\">Custom-built websites with smart automation & AI-powered features.<\/div>\r\n    <div class=\"hitl8gakbl\"><div class=\"hitl8gakbi\"><span style=\"display:inline-block;width:5px;height:5px;border-radius:50%;background:#dc2626;flex-shrink:0;margin-right:7px;\"><\/span><span>SEO-optimized & lightning fast<\/span><\/div><div class=\"hitl8gakbi\"><span style=\"display:inline-block;width:5px;height:5px;border-radius:50%;background:#dc2626;flex-shrink:0;margin-right:7px;\"><\/span><span>Smart features built for your business<\/span><\/div><\/div>\r\n  <\/div>\r\n  \r\n  <div class=\"hitl8gakct\">\r\n    <button class=\"hitl8gakbtn\" style=\"animation:hitl8gak-pulse 2.5s ease-in-out infinite;animation-delay:1s;\">Get Free Consultation <span style=\"opacity:.9;\">\u2192<\/span><\/button>\r\n    <div class=\"hitl8gakbr\">hit.land<\/div>\r\n  <\/div>\r\n<\/a>\r\n<\/div><br \/>\n<\/p>\n<p>Special Analysis by Omanet | Navigate Oman&#8217;s Market<\/p>\n<p>The significant increase in US pharmaceutical manufacturing investments driven by tariff threats presents <strong>both risks and opportunities for Omani businesses<\/strong>. With global drugmakers prioritizing domestic production, Oman-based pharmaceutical exporters could face <strong>heightened competition and supply chain disruptions<\/strong>. However, smart investors and entrepreneurs in Oman should consider <strong>diversifying into value-added services or niche pharmaceutical markets<\/strong> less vulnerable to US-centric policies, while exploring partnerships to stay integrated in global supply chains.<\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Global drugmakers are boosting US manufacturing and stockpiling inventory amid potential tariffs on imported medicines. Pfizer, AstraZeneca, and others have secured exemptions or pledged billions to expand operations, ensuring supply-chain resilience and investor confidence.<\/p>\n","protected":false},"author":12,"featured_media":8563,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[482],"tags":[3631,3629,3630],"class_list":["post-8562","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-economy","tag-drugmakers-investment","tag-pharmaceuticals","tag-us-manufacturing"],"jetpack_featured_media_url":"https:\/\/omanet.om\/wp-content\/uploads\/2026\/01\/3275982.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/posts\/8562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/comments?post=8562"}],"version-history":[{"count":1,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/posts\/8562\/revisions"}],"predecessor-version":[{"id":8564,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/posts\/8562\/revisions\/8564"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/media\/8563"}],"wp:attachment":[{"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/media?parent=8562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/categories?post=8562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/tags?post=8562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}